Intravenous proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: Determining statistical equivalence according to evidence-based methods

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 10, 2014, Pages 825-829

  Messori, Andrea ^a   Fadda, Valeria ^c   Maratea, Dario ^c   Gatto, Roberta ^a   Trippoli, Sabrina ^a   De Rosa, Mauro ^c   Marinai, Claudio ^b  

^a HTA Unit Area Vasta Centro Toscana Regional Health System   (Italy)

^b ESTAV Toscana Centro   (Italy)

^c BW Project Sifact Società Italiana di Farmacia Clinica e Terapia   (Italy)

Author keywords

Equivalence; Meta analysis; Omeprazole; Pantopra zole; Stress ulcer

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; ATTRIBUTABLE RISK; CONFIDENCE INTERVAL; CRITICALLY ILL PATIENT; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; PEPTIC ULCER BLEEDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); STRESS ULCER; SYSTEMATIC REVIEW; THERAPEUTIC EQUIVALENCE; TREATMENT OUTCOME; COMPLICATION; CRITICAL ILLNESS; INTRAVENOUS DRUG ADMINISTRATION; MENTAL STRESS; PEPTIC ULCER;

ADMINISTRATION, INTRAVENOUS; CRITICAL ILLNESS; EVIDENCE-BASED MEDICINE; HISTAMINE H2 ANTAGONISTS; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STRESS, PSYCHOLOGICAL;

EID: 84911971133     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202124     Document Type: Article

References (23)

1. Ahn S, Park SH, Lee KH. How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research. Radiology. 2013; 267: 328-338.
2. Arruda MA. No evidence of efficacy or evidence of no efficacy. JAMA Pediatr. 2013; 767: 300-302.
3. Messori A, Fadda V, Mara tea D, Trippoli S. Erythropoiesis-stimulating agents in heart failure: no proof of effectiveness or proof of no effectiveness? Eur J Heart Fail. 2013; 15: 944-945.
4. Messori A, Fadda V, Maratea D, Trippoli S. ω-3 fatty acid supplements for secondary prevention of cardiovascular disease: from "no proof of effectiveness" to "proof of no effectiveness". JAMA Intern Med. 2013; 173: 1466-1468.
5. Messori A, Fadda V, Maratea D, Trippoli S. Risk of myocardial infarction with oral direct thrombin inhibitors: trial sequential analysis based on two published data sets. Am J Cardiol. 2014; 113: 746-748.
6. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008; 61: 763-769.
7. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008; 61: 64-75.
8. van der Tweel I, Bollen C. Sequential meta-analysis: an efficient decision-making tool. Clin Trials. 2010; 7: 136-146.
9. Imberger G, Wetterslev J, Gluud C. Trial sequential analysis has the potential to improve the reliability of conclusions in meta-analysis. Contemp Clin Trials. 2013; 36: 254-255.
10. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ. 2013; 346 (feb 15 1): f839.
11. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011; 343 (nov24 1): d6898.
12. Messori A, Fadda V, Maratea D, Trippoli S. Outcomes with short-term versus long-term antiplatelet dual therapy after drug-eluting stenting: quantifying the equivalence margins. Int J Cardiol. 2014; 172: 469-470.
13. Messori A, Fadda V, Mara tea D, Trippoli S. Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference? Semin Thromb Hemost. 2014; 40: 269-270.
14. Messori A, Maratea D, Fadda V, Trippoli S. Risk of intracranial haemorrhage in patients with atrial fibrillation treated with novel oral anticoagulants: testing the equivalence margins between dabigratran, rivaroxaban and apixaban. Eur J Clin Pharmacol. 2014; 70: 505-506.
15. Gallego-Galisteo M, Villa-Rubio A, Alegre-del Rey E, Márquez-Fernández E, Ramos-Báez JJ. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther. 2012; 37: 301-307.
16. Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ. Biological treatments for moderate-to-severe psoriasis: indirect comparison. J Clin Pharm Ther. 2013; 38:121-130.
17. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogitra X Yancopoulos GD, Stahl N, Vitti R, Berliner A J, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119: 2537-2548.
18. Messori A, Maratea D, Marinai C. Intravenous proton pump inhibitors for bleeding in patients with acute peptic ulcer: determining statistical equivalence according to evidence-based methods (Abstract). Presented in part at the "Tredices-ima Conferenza Nazionale sulla Farmaceutica, Appropriatezza prescrittiva e controllo della spesa farmaceutica", SIF (Italian Society of Pharmacology), Catania (Italy), 23 January 2014
19. Italian Agency of Medicines (AIFA). "Decreto Balduzzi", Art. 15, comma 11-bis, Legge 7 agosto 2012 n. 135. Available at: http://www.agenzia-farmaco.gov.it/it/content/aggiornamento-al-15052013-delle-tabelle-con-lista-farmaci-di-classe-consentire-tutti-gli-ope. Last accessed: 16 January 2014.
20. Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013; 41: 693-705.
21. Reveiz L, Guerrero-Lozano R, Camacho A, Yara L, Mosquera PA. Stress ulcer, gastritis, and gastrointestinal bleeding prophylaxis in critically ill pediatric patients: a systematic review. Pediatr Crit Care Med. 2010; 11: 124-132.
22. Conrad SA, Gabrielli A, Margolis B, Quartin A, Hata JS, Frank WO, Bagin RG, Rock JA, Hepburn B, Laine L. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med. 2005; 33: 760-765.
23. Norman G, Monteiro S, Salama S. Sample size calculations: should the emperor's clothes be off the peg or made to measure? BMJ. 2012; 345 (aug23 1): e5278.